Articles related to INSOMNIA/SLEEP DISORDERS

Actigraphy devices revealed significant improvements in sleep patterns with nighttime levodopa use, despite patients not perceiving these changes subjectively.

CBTI offers a non-pharmacological approach to treating insomnia, focusing on behavioral changes that can lead to long-term improvements in sleep quality.

Amantadine emerges as the pharmacologic agent with the most support for improving cognitive impairment after TBI, while cognitive rehabilitation interventions demonstrate substantial evidence for enhancing neurocognitive function and reducing functional limitations.

Chronic insomnia affects about 10% of adults and is associated with increased risks of major depression, hypertension, Alzheimer’s disease, and work disability.

Clinicians should be vigilant about melatonin interactions with various medications such as antidepressants, blood thinners, and blood pressure drugs to ensure patient safety and effective treatment.

The study demonstrates that tirzepatide significantly reduces apnea–hypopnea index and body weight in patients with obstructive sleep apnea and obesity, indicating its potential role in improving both sleep and metabolic health.